BAGUERAC Cervical Disc Prosthesis
Spineart USA, Inc. · Decision date Aug 27, 2026
What did the FDA decide?
FDA records P250042/S001 as a supplement to PMA P250042, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 27, 2026.
FDA approval order statement
addition of a new raw material supplier, Industriekeramik Hochrhein (IKH), for titanium powder used in the plasma spray coating of BAGUERA C inferior and superior endplates
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Aug 27, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P250042/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Spineart USA, Inc.
- Product code
- MJO
- Decision code
- OK30
- Decision date
- Aug 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, intervertebral disc.
- Applicant
- Spineart USA, Inc.
- Product code
- MJO
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250042. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250042 · Original PMA
BAGUERAC Cervical Disc Prosthesis
P250042/S001 received
Application receipt date recorded by FDA.
P250042/S001 · FDA decision
30-Day Notice
P250042/S002 · Related supplement
BAGUERAC Cervical Disc Prosthesis
Timeline entries are records held by MedtechLedger for P250042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250042
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Spineart USA, Inc. | PMA approval | Aug 10, 2026 | FDA | |
BAGUERAC Cervical Disc ProsthesisP250042/S002 | Spineart USA, Inc. | PMA supplement | Sep 22, 2026 | FDA |
Explore the linked device profile
Other records with product code MJO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Synergy DiscP250028/S003 | Synergy Spine Solutions, Inc. | PMA supplement | Sep 17, 2026 | FDA |
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA | |
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA | |
prodisc C NovaP070001/S031 | Centinel Spine, LLC | PMA supplement | Sep 9, 2026 | FDA |
Synergy DiscP250028/S002 | Synergy Spine Solutions, Inc. | PMA supplement | Jul 6, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Spineart USA, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 23332 Mill Creek Dr., Suite 150, Laguna Hills, CA, 92653
Sources and methodology
- Original FDA record: P250042/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



